FDA Clearance Tracker · P990040-S001
TRUFILL(R) N-BUTYL CYANOACRYLATE (N-BCA) LIQUID EMBOLIC SYSTEM
Last checked: Nov 20, 2026Latest source record: May 30, 2001 (this decision)Source: openFDAMethods & limitations
Decided
May 30, 2001
Approved
Time to decision
90 days
Received Mar 1, 2001. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P990040-S001
- Device name
- TRUFILL(R) N-BUTYL CYANOACRYLATE (N-BCA) LIQUID EMBOLIC SYSTEM
- Applicant
- Cerenovus, Inc.
- Applicant location
- Miami, FL
- Received
- Mar 1, 2001
- Decided
- May 30, 2001
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Other
- Original approval
- P990040
Device type
- Device class
- Class III
- Specialty
- Neurology & Neurosurgery
FDA's approval statement
As written in FDA's record.
APPROVAL FOR REMOVAL OF THE POST ETHYLENE OXIDE STERILIZATION PYROGEN TEST OF THE N-BCA, REMOVAL OF THE POST-STERILIZATION FUNCTIONAL TESTING OF THE TANTALUM POWDER, THE ADDITION OF A PYROGEN TEST OF THE TANTALUM POWDER, AND THE VALIDATION OF THE PYROGENICITY TEST.
Source documents
Other decisions for Cerenovus, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262419 · Decided Aug 14, 2026 · 30 days after receipt
Device type: Device, Neurovascular Embolization (HCG) · Neurology & Neurosurgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.